Targeted skin Blueberry Therapeutics focuses on skin diseases and has programs in Onychomycosis, Tinea Pedis, Acne and Atopic Dermatitis, indicating opportunities for partnerships or co-development in dermatology drug discovery and preclinical services.

Early-stage focus As a small biotech with 2-10 employees and ongoing preclinical to early clinical concepts, they may need outsourced research, CRO support, and lightweight clinical operations to accelerate timelines and de-risk development.

Funding runway With a total funding of $23M and recent investor activity, there is appetite for strategic collaborations, licensing deals, or milestone-driven partnerships to advance programs and expand capabilities.

Clinical design They emphasize smart, agile trial designs and low toxicity liabilities, suggesting interest in advisory, biomarker strategy, regulatory consulting, and patient-centric trial optimization services.

Growth potential Recent hires in clinical science leadership and project management indicate scale-up plans; opportunities exist to provide translational research, GMP materials, manufacturing support, or long-term development partnerships.